Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: Early results from a single institution-Reference-Cited by-同舟云学术

Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: Early results from a single institution

Published:2013-12-16 Issue:2 Volume:18 Page:217-220
ISSN:1397-3142
Container-title:Pediatric Transplantation
language:en
Short-container-title:Pediatr Transplantation

Author:

Soni Sandeep¹,Pai Vinita¹²,Gross Thomas G.¹,Ranalli Mark¹

Affiliation:

1. Division of Hematology/Oncology/BMT; Nationwide Children's Hospital; Columbus OH USA

2. College of Pharmacy; The Ohio State University; Columbus OH USA

Publisher

Wiley

Subject

Transplantation,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/petr.12202/fullpdf

Reference11 articles.

1. Purged versus non-purged peripheral blood stem-cell transplantation for high risk neuroblastoma (COG 3973): A randomized phase 3 trial;Kriessman;Lancet Oncol,2013

2. Busulfan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial;Landenstein;J Clin Oncol,2011

3. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study;Ladenstein;J Clin Oncol,2010

4. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma;Yu;N Engl J Med,2010

5. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment;Brodeur;J Clin Oncol,1993

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR-Cas System Is an Effective Tool for Identifying Drug Combinations That Provide Synergistic Therapeutic Potential in Cancers;Cells;2023-11-09

2. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1;Transplantation and Cellular Therapy;2021-06

3. Upfront consolidation treatment with 131 I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma;Pediatric Investigation;2020-09

4. Cabozantinib for relapsed neuroblastoma: Single institution case series;Pediatric Blood & Cancer;2020-04-28

5. Blood product administration during high risk neuroblastoma therapy;Pediatric Hematology and Oncology;2019-12-12